|
Trendlines Tips | |
It's Always Something
 By D. Todd Dollinger, Chairman and CEO of The Trendlines Group
In the immortal words of Roseanne Roseannadanna, "It just goes to show you, it's always something. If it ain't one thing, it's another." And, sometimes, that thing looks the same, time and again. When we realize - again - that only uncertainty is certain, thoughts go to whom we work with, and whom we invest in. READ MORE |
|
News from The Trendlines Group |
Todd Represents Trendlines at the 2011 Israel Conference
Todd Dollinger was a panel participant and speaker at the 2011 Israel Conference held in Los Angeles on June 2. The Israel Conference™ encompasses a full day of dialogue with global leaders, prominent investors, and internationally recognized industry executives gathering to discuss the vitality and growth of Israel-facing business through a variety of panels on hot industry topics and trends. Attendees were  from high tech, clean tech, medical tech, consumer products, energy, security, and entertainment media technology. Throughout the day, CEOs of Israel-facing companies and VCs spoke about their successes, breakthrough technologies, markets, deals, and exits. Watch an interview with Todd from the conference.
|
|
Trendlines in the Community |
Trendlines Joins Tmura, Israeli Public Service Fund
The Trendlines Group recently became a member of Tmura, the Israeli Public Service Venture Fund, a foundation that was established by leading Israeli venture capital funds to involve the high-tech sector in supporting charitable activities.  The unique business model is simple: participating early-stage companies give Tmura a warrant, convertible (at exit) into a small portion of their equity. When the company succeeds, Tmura sells its shares and donates the proceeds to charities in Israel; the focus is on education and youth-related activities, and the companies can indicate which organizations they want to support. Trendlines is proud to support this effort. For more information, see the Tmura website.
|
|
Upcoming Events |
Misgav Venture Accelerator Booth at SMIT in Tel Aviv
2012 U.S. Investor Road Show in Planning Stages
The Trendlines Group is pleased to anounce our 2nd Annual U.S. Investor Road Show will take place at the end of March 2012. We are currently finalizing the cities for our intense five-day tour that will include portfolio companies from both of our incubators: Misgav Venture Accelerator and Mofet Venture Accelerator. Our extremely successful 2011 U.S. Investor Road Show featured 14 of our portfolio companies, including start-ups in the life sciences, medical device, agritech, and cleantech industries. Event attendees included angel investors seeking seed- and early-stage Israel-based investment opportunities, venture capitalists, investment bankers, and potential strategic partners for our companies. Stay tuned! We will announce our city stops in the next month and will look to align with both professional and media sponsors in each city. |
|
The Trendlines Portfolio |
Immunovative Subsidiary Going Public in U.S.
Immunovative Therapies Ltd., a portfolio company of The Trendlines Group's Misgav Venture Accelerator, announced that its wholly-owned U.S. subsidiary, Immunovative Clinical Research, Inc. (ICRI), signed a Memorandum of Understanding to be acquired by Novo Energies Corp (OTCBB:NVNC). The terms of the agreement will leave ICRI as the controlling owner of the merged entity. As part of the merger agreement, Novo Energies will contribute a minimum of $5 million to finance advancement of Immunovative's lead product, AlloStim, to Phase II/III clinical trials. Immunovative develops treatments designed to harness the power of the immune system to seek out and destroy cancer where it resides in the body and to remember the cancer so that if the cancer returns, an immune mediated attack can be reinstated to prevent disease recurrence.
SolChip Featured on Israel21C
Read this recent article which focuses on SolChip's eco-friendly renewable battery technology for low-power devices which may be used in farming, agriculture, healthcare and other industries. Israel's SolChip has "a cure for the battery blues," the article reports.
MicroPointing Featured on CNET
MicroPointing and the company's fingertip mouse were recently featured on the CRAVE blog, part of CNET News. "This could herald a trend toward fingertip controls," the author states. Read the full article here.
Trendlines investors can access additional information on our portfolio companies through the password protected page on our website.
|
|
|
The 9 Most Important Things to Remember If You Want to Sell Your Startup
Recently on Tech Crunch, investor, programmer, author, and entrepreneur James Altucher wrote, "As soon as I start a company, I want to sell it. I've sold four companies and I'm invested in another dozen that have been through various stages of the selling process. It's not pleasant, it's ugly, and everyone paints a pretty face so they look good on the first date..." Read what Altucher recommends in regards to selling a start up. |
|
|
Juvenis Raises $300,000
Juvenis, developer of large-volume bio-fillers for aesthetic and plastic procedures, has raised $300,000. Juvenis plans to revolutionize the $10 billion breast augmentation market by providing a safe, natural looking, non-surgical method for breast augmentation, making it easy to perform the procedure, as well as minimizing complications and scarring.
IonMed Raises Funds for Clinical Trials
IonMed, which has developed a novel device that welds surgical incisions using cold plasma, has closed its second financing round. IonMed's device makes for shorter procedure times, minimal scarring and is expected to reduce surgical wound infection rates. The device was successfully tested in initial clinical trials.
Headway Received a $465k Investment from Israeli CRO
A portfolio company of The Trendlines Group's Misgav Venture Accelerator Headway recently announced a $465,000 raise from an Israeli CRO (contract research organization).
VivoText Raised $400k from Private Investors
A portfolio company of The Trendlines Group's Mofet Venture Accelerator VivoText announced a raise from private investors of $400,000. VivoText has developed software that converts written text to speech with the quality of expressive, human speech. VivoText has completed building the first prototype in English.
|
|
|
|
|
|
Staff News |
After six years of successfully leading our business development consultancy - starting with Trendlines International which was later rebranded as Signal Business Development - we are very pleased to announce that Tina Ornstein has been elected CEO of NovoSpeech Ltd. NovoSpeech, a portfolio company of The Trendlines Group's Mofet Venture Accelerator, has developed a high-performance automatic speech recognition (ASR) engine which provides a superior solution for a wide variety of applications, including computer-assisted speech therapy and Bluetooth headsets. Tina brings 20 years of experience in management, professional services, business development and sales to NovoSpeech as it enters its commercialization phase. We thank Tina for the tremendous value she has brought to The Trendlines Group in general and to our business development consultancy, in particular. We know that she will be a great success in this new endeavor.
|
|
|
